ALTTO Test of Dual HER2 Blockade Finds Single Agent - Trastuzumab - Remains Gold Standard

http://www.youtube.com/watch?v=PAyvFbGlWKY&feature=youtu.be Journalists: Broadcast soundbites with Dr. Perez are available in the downloads. CHICAGO — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news